Brief: Prelude Therapeutics Receives FDA Clearance Of Investigational New Drug Application (Ind) For Prt12396, A Mutant-Selective Jak2v617f Inhibitor
03/02/2026 14:04
Feb 3 (Reuters) - Prelude Therapeutics Inc PRLD.O: PRELUDE THERAPEUTICS RECEIVES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR PRT12396, A MUTANT-SELECTIVE JAK2V617F INHIBITOR PRELUDE THERAPEUTICS INC - TO DOSE FIRST PATIENT BY Q2 2026 Source text: ID:nGNX6m9NC8 Further company coverage: PRLD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview